Aranesp is Amgen's biggest product, with $4.12 billion in sales in 2006.
Aranesp是阿目金公司最主要的产品,2006年的销售额是41.2亿美元。
A federal judge has ruled that Mircera, a Roche anemia drug that would compete with Amgen's Epogen and Aranesp, violates an Amgen patent.
一次联邦审判认定Mircera,一个罗氏生产的用于同安进的Epogen和Aranesp竞争的药物,触犯了安进的专利权。
Among the patients who received Aranesp to treat their anemia, 14% had died after three years, compared with 9.8% of those who did not receive Aranesp.
在这些病人中,应用Aranesp治疗贫血(化疗引起)的病人三年死亡率14%,而不用Aranesp的病人三年死亡率9.8%。
应用推荐